Pembrolizumab-induced dual endocrine disruption: A case report

María Carmen Dameto Pons1, Elena González Arnáiz1, María Antequera González1

  • 1Servicio de Endocrinología y Nutrición, Complejo Asistencial Universitario de León, Gerencia de Salud de Castilla y León (SACYL), Altos de Nava s/n, 24071 León, Spain.

PubMed
Summary

Cancer immunotherapy, particularly PD-1/PD-L1 inhibitors, can cause autoimmune endocrine side effects like thyroid disorders and diabetes. A melanoma patient on pembrolizumab developed both thyroiditis and fulminant autoimmune diabetes.